ES2494442T3 - Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico - Google Patents

Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico Download PDF

Info

Publication number
ES2494442T3
ES2494442T3 ES10721036.1T ES10721036T ES2494442T3 ES 2494442 T3 ES2494442 T3 ES 2494442T3 ES 10721036 T ES10721036 T ES 10721036T ES 2494442 T3 ES2494442 T3 ES 2494442T3
Authority
ES
Spain
Prior art keywords
isotonicity agent
adjuvant compositions
ionic
ionic isotonicity
adjuvant composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10721036.1T
Other languages
English (en)
Inventor
Veronique Henderickx
Dominique Ingrid Lemoine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2494442(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2494442T3 publication Critical patent/ES2494442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición adyuvante acuosa que comprende: (a) un agonista de TLR-4 y una saponina, en una formulación liposomal; y (b) un agente de isotonicidad no iónico, en la que la concentración de cloruro de sodio o el potencial iónico en la composición adyuvante es menor de 100 mM.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
ES10721036.1T 2009-06-10 2010-06-08 Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico Active ES2494442T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
GB0910046 2009-06-10
PCT/EP2010/058017 WO2010142685A1 (en) 2009-06-10 2010-06-08 Adjuvant compositions comprising a non-ionic isotonicity agent

Publications (1)

Publication Number Publication Date
ES2494442T3 true ES2494442T3 (es) 2014-09-15

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10721036.1T Active ES2494442T3 (es) 2009-06-10 2010-06-08 Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico

Country Status (31)

Country Link
US (2) US20120087976A1 (es)
EP (1) EP2440242B1 (es)
JP (3) JP5647677B2 (es)
KR (1) KR101473686B1 (es)
CN (2) CN102458457B (es)
AU (1) AU2010257538B2 (es)
BR (1) BRPI1012890B1 (es)
CA (1) CA2764421C (es)
CL (1) CL2011003113A1 (es)
CO (1) CO6440528A2 (es)
CY (1) CY1115522T1 (es)
DK (1) DK2440242T3 (es)
DO (1) DOP2011000346A (es)
EA (1) EA024074B1 (es)
ES (1) ES2494442T3 (es)
GB (1) GB0910046D0 (es)
HR (1) HRP20140792T1 (es)
IL (1) IL216231A0 (es)
MA (1) MA33412B1 (es)
MX (1) MX2011013162A (es)
MY (1) MY159819A (es)
NZ (1) NZ596503A (es)
PE (1) PE20120319A1 (es)
PL (1) PL2440242T3 (es)
PT (1) PT2440242E (es)
RS (1) RS53550B1 (es)
SG (1) SG176638A1 (es)
SI (1) SI2440242T1 (es)
SM (1) SMT201400134B (es)
UA (1) UA104888C2 (es)
WO (1) WO2010142685A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33418B1 (fr) 2009-06-10 2012-07-03 Chugai Pharmaceutical Co Ltd Composé tétracyclique
KR101362589B1 (ko) 2010-08-20 2014-02-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 포함하는 조성물
CN103260642B (zh) * 2010-12-14 2018-03-16 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
LT2902029T (lt) 2012-09-25 2018-10-25 Chugai Seiyaku Kabushiki Kaisha Ret inhibitorius
CN107124869B (zh) * 2014-03-25 2022-04-01 美国政府陆军部 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂
SG10202009484WA (en) 2014-04-25 2020-11-27 Chugai Pharmaceutical Co Ltd Preparation containing tetracyclic compound at high dose
KR20160142383A (ko) 2014-04-25 2016-12-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
CN110035770B (zh) * 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 新方法
JP2020536946A (ja) * 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
BR112020010635A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. extração de saponina
JP2021504424A (ja) * 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
MX2021002311A (es) 2018-09-04 2021-04-28 Chugai Pharmaceutical Co Ltd Metodo para producir un compuesto tetraciclico.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
CN1087176C (zh) * 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DK1659179T3 (da) 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
JP2002513773A (ja) * 1998-05-07 2002-05-14 コリクサ コーポレイション アジュバント組成物及びその使用法
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1829887B1 (en) * 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Cpg single-strand deoxynucleotides for use as adjuvant
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
TWI434697B (zh) 2007-01-15 2014-04-21 Glaxosmithkline Biolog Sa 疫苗
DK2118128T3 (da) 2007-01-15 2013-02-18 Glaxosmithkline Biolog Sa Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1
US20090035360A1 (en) * 2007-05-24 2009-02-05 Dominique Ingrid Lemoine Lyophilised antigen composition
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
EA201190286A1 (ru) 2012-06-29
MY159819A (en) 2017-02-15
JP2016193912A (ja) 2016-11-17
CN102458457B (zh) 2015-05-20
CO6440528A2 (es) 2012-05-15
JP5647677B2 (ja) 2015-01-07
JP5977789B2 (ja) 2016-08-24
NZ596503A (en) 2013-08-30
JP6261647B2 (ja) 2018-01-17
JP2012529464A (ja) 2012-11-22
GB0910046D0 (en) 2009-07-22
DOP2011000346A (es) 2012-01-15
BRPI1012890B1 (pt) 2022-03-22
PL2440242T3 (pl) 2014-11-28
US20180021417A1 (en) 2018-01-25
AU2010257538B2 (en) 2016-10-20
CL2011003113A1 (es) 2012-08-31
CN102458457A (zh) 2012-05-16
IL216231A0 (en) 2012-01-31
BRPI1012890A2 (pt) 2018-02-27
CA2764421C (en) 2016-12-06
CY1115522T1 (el) 2017-01-04
WO2010142685A1 (en) 2010-12-16
SI2440242T1 (sl) 2014-09-30
CN104367997B (zh) 2019-01-22
EA024074B1 (ru) 2016-08-31
MA33412B1 (fr) 2012-07-03
UA104888C2 (uk) 2014-03-25
RS53550B1 (en) 2015-02-27
JP2015042646A (ja) 2015-03-05
HRP20140792T1 (hr) 2014-10-10
CN104367997A (zh) 2015-02-25
EP2440242B1 (en) 2014-06-25
PT2440242E (pt) 2014-08-29
EP2440242A1 (en) 2012-04-18
AU2010257538A1 (en) 2011-12-08
DK2440242T3 (da) 2014-09-01
SG176638A1 (en) 2012-01-30
US20120087976A1 (en) 2012-04-12
SMT201400134B (it) 2014-11-10
MX2011013162A (es) 2012-01-30
KR101473686B1 (ko) 2014-12-18
CA2764421A1 (en) 2010-12-16
PE20120319A1 (es) 2012-04-16
KR20120031497A (ko) 2012-04-03

Similar Documents

Publication Publication Date Title
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2483725T3 (es) Composición básica cosmética y su uso
AR084285A1 (es) Composiciones inmunogenicas
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
ES2478820T3 (es) Tratamiento de degeneración macular
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
PE20120326A1 (es) Formulaciones farmaceuticas para reducir la proliferacion y viabilidad de los agentes microbianos
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
PE20110162A1 (es) Yoduro de povidona, un nuevo conservante alternativo para composiciones oftalmicas
BR112022019073A2 (pt) Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
AR108718A2 (es) Composición
BR112017012978A2 (pt) composições adjuvantes aquosas contendo eletrólitos, composições contendo substância ativa e o uso das mesmas
AR108083A1 (es) Composiciones, kits y métodos para mantener la higiene del párpado
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
RS52150B (en) PELLETS CONTAINING VENLAFAKSIN HYDROCHLORIDE
CL2012001545A1 (es) Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras.
AR053144A1 (es) Composicion farmaceutica solida que comprende telitromicina
AR044449A1 (es) Composiciones acuosas desinfectantes y/o bactericidas
AR065703A1 (es) Uso de una micro - emulsion acuosa para la preparacion de una formulacion para el tratamiento de enfermedades adiposas y dicha micro - emulsion